NCT03027388: Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma |
|
|
| Completed | 2 | 7 | US | LB-100 | National Cancer Institute (NCI) | Astrocytoma, Grades II, III and IV, Glioblastoma Multiforme, Giant Cell Glioblastoma, Glioma, Oligodendrogliomas | 08/22 | 08/22 | | |
NCT03886662: A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) |
|
|
| Unknown status | 1b/2 | 47 | US | LB-100 | Lixte Biotechnology Holdings, Inc. | Myelodysplastic Syndromes | 05/21 | 07/21 | | |
2019-003034-16: Trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas Ensayo de LB-100 más doxorrubicina vs. doxorrubicina sola en primera lnea de sarcomas de tejidos blandos avanzados |
|
|
| Not yet recruiting | 1/2 | 152 | Europe | Doxorubicin, LB-100, Solution for infusion, Solution for injection, Doxorubicina Accord | Grupo Español de Investigación en Sarcomas (GEIS), Lixte Biotechnology Holdings, Inc. | Advanced/metastatic soft tissue sarcoma (undifferentiated pleomorphic sarcoma, leiomyosarcoma, myxoid and hypercellular myxoid liposarcoma, myxofibrosarcoma, NOS sarcoma, synovial sarcoma, fibrosarcoma, or malignant nerve sheath tumor) Sarcoma de tejidos blandos avanzado/metastásico (sarcoma pleomórfico indiferenciado, leiomiosarcoma, liposarcoma mixoide y liposarcoma hipercelular mixoide, mixofibrosarcoma, sarcomas no especificados en otra categoría, sarcoma sinovial, fibrosarcoma o tumor maligno de la vaina del nervio periférico), Advanced/metastatic soft tissue sarcoma Sarcoma de tejidos blandos avanzado/metastásico, Diseases [C] - Cancer [C04] | | | | |
Enhancer, NCT05809830: Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas |
|
|
| Recruiting | 1/2 | 152 | Europe | LB-100 plus Doxorrubicin, Doxorubicin | Grupo Espanol de Investigacion en Sarcomas | Advanced Soft-tissue Sarcoma | 06/25 | 05/26 | | |
NCT06065462: Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100 |
|
|
| Recruiting | 1/2 | 21 | US | Dostarlimab, LB-100 | M.D. Anderson Cancer Center, GSK Pharma, Lixte | Ovarian Clear Cell Carcinoma | 01/26 | 01/26 | | |
